Crohn's disease: Is there a place for neurological screening?

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 173-176

  Stovicek, Jan ^a   Liskova, Petra ^a   Lisy, Jiri ^a   Hlava, Stepan ^a   Keil, Radan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Crohn's disease; Demyelinating diseases; Inflammatory bowel diseases; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN; BRAIN ATROPHY; CENTRAL NERVOUS SYSTEM; CROHN DISEASE; DEMYELINATING DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; WHITE MATTER; WHITE MATTER LESION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CROHN DISEASE; DEMYELINATING DISEASES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84892769193     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.867358     Document Type: Article

References (14)

1. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129:827-36.
2. Gupta G, Gelfand JM, Lewis JD. Increased risk of demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819-26.
3. Singh S, Kumar N, Loftus EV, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis 2013;19:864-72.
4. Oliveira GR, Teles BC, Brasil EF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis 2008;14:389-95.
5. Chen M, Lee G, Kong LN, Lamont S, Chaves C. Cerberal white matter lesions in patients with Crohn-s disease. J Neuroimaging 2012;22:38-41.
6. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebocontrolled multicenter study. Neurology 1999;53:457.
7. Kollias D, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis,multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999;169: 175-94.
8. Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 2011;342:352-5.
9. Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 2010; 257:1421-31.
10. Lin J, Zitiny D, Desai S, et al. TNFalfa blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30.
11. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.
12. Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, et al. Demyelinating disease following Anti-TNFa Treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013;2013:671935.
13. Pugliatti M, Rosami G, Karton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of muliple sclerosis in Europe. Eur J Neurol 2006;13:700-22.
14. TheWorldBankDatabase. Available fromdataworldbank. org.